Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pentostatin
Drug ID BADD_D01730
Description A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Indications and Usage For the treatment of hairy cell leukaemia refractory to alpha interferon.
Marketing Status approved; investigational
ATC Code L01XX08
DrugBank ID DB00552
KEGG ID D00155
MeSH ID D015649
PubChem ID 439693
TTD Drug ID D0T3AD
NDC Product Code 42533-109; 67457-288; 0409-0801; 14096-124; 59981-005
UNII 395575MZO7
Synonyms Pentostatin | Deoxycoformycin | Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (R)- | 2'-Deoxycoformycin | 2' Deoxycoformycin | NSC-218321 | NSC 218321 | NSC218321 | Co-Vidarabine | CI-825 | CI 825 | CI825 | Nipent
Chemical Information
Molecular Formula C11H16N4O4
CAS Registry Number 53910-25-1
SMILES C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insomnia19.02.01.002; 17.15.03.002--
Labyrinthitis11.01.05.002; 04.04.03.001--Not Available
Lacrimation disorder06.08.02.010--Not Available
Lacrimation increased06.08.02.004--
Laryngeal oedema10.01.05.003; 23.04.01.005; 22.04.02.001--
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.003--Not Available
Lung disorder22.02.07.001--Not Available
Meningism17.02.05.007--
Mental disability26.01.01.001--Not Available
Metastases to liver16.22.02.001; 09.04.02.0040.000168%Not Available
Mood swings19.04.03.001--Not Available
Muscle twitching15.05.03.005--Not Available
Myalgia15.05.02.001--
Nausea07.01.07.0010.000112%
Neoplasm16.16.02.001--Not Available
Nephrolithiasis20.04.01.002--
Nephropathy20.05.03.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuralgia17.02.07.005--
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neurosis19.06.01.001--Not Available
Neurotoxicity17.02.10.002; 12.03.01.0110.000112%Not Available
Neutropenia01.02.03.0040.000168%Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages